Abstract
BackgroundTofacitinib, baricitinib, upadacitinib and filgotinib are the Janus kinase inhibitors (JAKi) approved for the treatment of rheumatoid arthritis (RA) in the UK. We report our real-world experience in a cohort...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
